Virtual compound screening in drug discovery.

Area of Science:

• Computational chemistry
• Drug discovery
• Pharmacology

Background:

• Virtual screening (VS) encompasses ligand- and target structure-based methods, widely used in academia and drug discovery.
• The field is evolving, marked by scientific heterogeneity and ongoing debate regarding its value compared to experimental high-throughput screening (HTS).

Purpose of the Study:

• To discuss the current state-of-the-art in virtual screening.
• To evaluate the successes, limitations, and future potential of VS in drug discovery.
• To highlight the underutilization of VS's complementarity with HTS.

Main Methods:

• Review and discussion of current virtual screening methodologies.
• Analysis of VS applications and successes in identifying novel drug candidates.
• Exploration of the interface between computational and experimental screening approaches.

Main Results:

• VS has successfully identified novel hits, including first-in-class compounds and new chemotypes, despite its limitations.
• The full potential of VS remains underutilized due to insufficient exploitation of its synergy with HTS.
• There is significant room for improvement in VS method evaluation and application.

Conclusions:

• Virtual screening is an established tool in pharmaceutical research with proven success in hit identification.
• Enhanced integration and close collaboration between computational VS and experimental HTS are crucial for streamlining drug discovery.
• Further advancements in VS methods and strategic application are needed to maximize its impact.